ARYx Therapeutics
closedPharmaceutical company focused on retrometabolic drug designing and improving the safety of oral therapies for chronic diseases.
Launch date
Employees
Market cap
€216k
Enterprise valuation
€216k (Public information from Sep 2024)
Share price
$0.0005 ARYX
Fremont California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$25.0m | Series C | ||
$55.0m | Series D | ||
$30.4m | Series E | ||
| N/A | N/A | IPO | |
$21.6m | Private Placement VC | ||
$360k | Post IPO Equity | ||
$6.3m | Debt | ||
| Total Funding | €120m | ||